Compare · MRK vs PCSA
MRK vs PCSA
Side-by-side comparison of Merck & Company Inc. (MRK) and Processa Pharmaceuticals Inc. (PCSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and PCSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $284.45B, about 49487.9x PCSA ($5.7M).
- Over the past year, MRK is up 47.2% and PCSA is down 68.1% - MRK leads by 115.3 points.
- MRK has been more active in the news (23 items in the past 4 weeks vs 10 for PCSA).
- MRK has more recent analyst coverage (25 ratings vs 3 for PCSA).
- Company
- Merck & Company Inc.
- Processa Pharmaceuticals Inc.
- Price
- $115.26+0.31%
- $2.10-7.28%
- Market cap
- $284.45B
- $5.7M
- 1M return
- +3.51%
- -30.00%
- 1Y return
- +47.22%
- -68.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 23
- 10
- Recent ratings
- 25
- 3
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Processa Pharmaceuticals Inc.
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland.
Latest MRK
- Merck Animal Health to Acquire TARGAN
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
Latest PCSA
- Pres. Research & Development Young David bought $4,589 worth of shares (2,067 units at $2.22), increasing direct ownership by 12% to 19,198 units (SEC Form 4)
- Chief Financial Officer Skibsted Russell bought $5,892 worth of shares (2,654 units at $2.22), increasing direct ownership by 25% to 13,412 units (SEC Form 4)
- Chief Executive Officer Ng George K bought $5,472 worth of shares (2,465 units at $2.22), increasing direct ownership by 25% to 12,435 units (SEC Form 4)
- Chief Business - Strategy Off Lin Patrick bought $4,065 worth of shares (1,831 units at $2.22), increasing direct ownership by 20% to 11,007 units (SEC Form 4)
- Chief Administrative Officer Guy Wendy bought $4,702 worth of shares (2,118 units at $2.22), increasing direct ownership by 22% to 11,958 units (SEC Form 4)
- Pres. Research & Development Young David bought $4,590 worth of shares (1,786 units at $2.57), increasing direct ownership by 12% to 17,131 units (SEC Form 4)
- Chief Financial Officer Skibsted Russell bought $5,890 worth of shares (2,292 units at $2.57), increasing direct ownership by 27% to 10,758 units (SEC Form 4)
- Chief Executive Officer Ng George K bought $5,472 worth of shares (2,129 units at $2.57), increasing direct ownership by 27% to 9,970 units (SEC Form 4)
- Chief Business - Strategy Off Lin Patrick bought $4,066 worth of shares (1,582 units at $2.57), increasing direct ownership by 21% to 9,176 units (SEC Form 4)
- Chief Administrative Officer Guy Wendy bought $4,701 worth of shares (1,829 units at $2.57), increasing direct ownership by 23% to 9,840 units (SEC Form 4)